Christoph B.
- Country
- Germany
- Department
- Internal Medicine I – Gastroenterology, GI Oncology, Hepatology, etc
Research Overview
- Phase2, double-blind, randomized, placebo-controlled, multicentre study to evaluation the safety, efficacy, and pharmacokinetics of TAK-242 and Granulocyte Colony-Stimulating Factor (G-CSF) (G-TAK) in subjects with severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF).
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Non-Cirrhotic NASH/MASH with Fibrosis
Data & Insights
Has run more than one trial at 94 of 238 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating various forms of primary sclerosing cholangitis (PSC), including innovative approaches to managing associated symptoms like pruritus. Their work extends to the treatment of intrahepatic biliary tract cancer.
- Novel therapeutic approaches for PSC
- Biliary tract cancer interventions
- Symptom management in cholangitic conditions
Hepatic Disorders
The investigator focuses on treating complex liver conditions including liver cirrhosis and metabolic dysfunction-associated steatohepatitis (MASH). Their expertise includes management of polycystic liver disease and innovative treatments for liver fibrosis.
- Cirrhosis management protocols
- MASH/NASH treatment strategies
- Polycystic liver disease interventions
Advanced Liver Care
Specialized in treating alcohol-related liver disease and acute-on-chronic liver failure (ACLF). The investigator also has expertise in liver transplant medicine, including post-transplant care and rejection prevention protocols.
- Alcoholic liver disease treatment
- ACLF management
- Transplant recipient care
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.